<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859856</url>
  </required_header>
  <id_info>
    <org_study_id>2018.10.23</org_study_id>
    <nct_id>NCT03859856</nct_id>
  </id_info>
  <brief_title>Ovarian Reserve in Diabetes Mellitus</brief_title>
  <official_title>Ovarian Reserve in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes mellitus is a common autoimmune disease. It affects women of all ages
      including reproductive years. Hyperglycemic condition in diabetes can cause organ damage.
      This study aims to measure serum hormones including FSH, LH, E2, AMH, ovarian volume and
      antral follicle count (indicators of ovarian reserve) in women with and without type 1
      diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes mellitus is a common autoimmune disease. It affects women of all ages
      including reproductive years. It is showed that hyperglycemic state in diabetes results in
      organ damage like kidneys and eyes. Ovarian reserve is important for the reproductive period.
      The measurements of serum hormones including follicle stimulating hormone (FSH), luteinizing
      hormone (LH), estradiol (E2) and anti-mullerian hormone (AMH) will give us an idea about the
      ovarian reserve. The investigators aim is to measure ovarian reserve parameters in patients
      diagnosed with type 1 diabetes mellitus and to compare them to healthy controls. Serum FSH,
      LH, E2 and AMH will be measured on the 3rd day of the cycle. Antral follicle count and
      ovarian volume measurement will be done with ultrasonography. Ovarian reserve markers will be
      compared between the groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2018</start_date>
  <completion_date type="Actual">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>E2, FSH, LH, AMH levels</measure>
    <time_frame>during procedure</time_frame>
    <description>E2, FSH, LH, AMH levels of blood samples will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antral follicle count</measure>
    <time_frame>during procedure</time_frame>
    <description>antral follicles of ovaries will be counted with ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ovarian volume</measure>
    <time_frame>during procedure</time_frame>
    <description>both ovaries will be measured in three dimensions with ultrasonography</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>women with Type 1 diabetes mellitus</arm_group_label>
    <description>Reproductive age women diagnosed with type 1 diabetes mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>women without Type 1 diabetes mellitus</arm_group_label>
    <description>Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hormone panel and ultrasonography</intervention_name>
    <description>Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.</description>
    <arm_group_label>women with Type 1 diabetes mellitus</arm_group_label>
    <arm_group_label>women without Type 1 diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be reproductive age women diagnosed with type 1 diabetes
        mellitus. The control population will be aged and BMI matched women without type 1 diabetes
        mellitus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reproductive age group women: 18-40 years

          -  Women diagnosed with type 1 diabetes (case group)

          -  Women without type 1 diabetes (control group)

        Exclusion Criteria:

          -  Women with PCOS (polycystic ovary syndrome)

          -  history of ovarian surgery

          -  Body mass index (BMI) over 30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kanuni SSTRH</name>
      <address>
        <city>Istanbul</city>
        <zip>34150</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>August 25, 2019</last_update_submitted>
  <last_update_submitted_qc>August 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Berna Aslan Cetin</investigator_full_name>
    <investigator_title>Md, ObGYN</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

